Drugs / 68Ga-NODAGA-SNA006
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07597772 | Oct 2025 → Jul 2026 overdue | malignant pancreatic neoplasm | SmartNuclide Biopharma | Recruiting | No outcome recorded |
| Phase 0 | NCT05126927 | Nov 2021 → Jan 2022 | cancer | SmartNuclide Biopharma | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07059832 | Apr 2024 → Jan 2028 expected | cancer | First Hospital of China Medical University | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NODAGA-SNA006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07059832 ↗ |
| Modality | Protein / enzyme biologic | “A novel nanobody without a hexahistidine (His6) tag, SNA006-GSC, was designed, site-specifically conjugated with NODAGA-maleimide and radiolabelled with 68 Ga.” PMID 35829748 ↗ Jul 2022 |
| Route | Intravenous | “Intravenous injection of SNA006 was used to observe its safety tolerance, radiation absorbed dose, distribution, and PET imaging characteristics in patients with solid tumors.” NCT05126927 ↗ |